Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab vs Chemotherapy in 2L Advanced ESCC
NCT03430843Phase 3Completed
- Sponsor
- BeiGene
- Start
- Jan 2018
- Primary completion
- Dec 2020
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by BeiGene. Started Jan 2018; status: completed.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03430843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03430843.